reteiP schreef: ↑18 augustus 2021, 13:36 Sterke stijging Arbutus (+16%) na een artikel in Forbes over de origine van mRNA technologie en de patenten errond.

Van belang is het 'four lipid delivery model' waar zowel Pfizer/Biontech als Moderna gebruik van (lijken) te maken. Vele patenten zaten een tijd lang in handen van Arbutus (ABUS), toen nog anders genaamd. En sommige patenten dus nog steeds. Patent misbruik aanvechten kan in deze huidige miljardenbusiness best interessant zijn, zelfs een settlement is een smak geld voor een biotech met enkel maar een pipeline.

Shares of Arbutus Biopharma closed up 15% amid speculation it has won a patent fight against Moderna.

• Arbutus may receive a new patent and as a result, may be eligible for royalties from Moderna from sales of its COVID-19 vaccine.
• The U.S. Patent and Trademark Office website shows that Arbutus was granted a notice of allowance on Sept. 2 for a patent covering novel lipid formulations for nucleic acid delivery.
• In the past, Moderna has unsuccessfully challenged similar patents.
• Moderna is appealing the validity of those patents with a hearing before a federal appellate court on Oct. 7

• Data from more than 32.8K hospital emergency department ("ED") or urgent care visits between June and August indicates that patients who received the Moderna (MRNA) COVID-19 shot have the highest level of vaccine effectiveness.
• CDC researchers found that among people with ED or urgent care visits, Moderna's vaccine efficacy was 92%. That compares to 77% for the Pfizer (PFE)/BioNTech (BNTX) vaccine, and 65% for the Johnson & Johnson (JNJ) shot.
• Vaccine effectiveness of the three vaccines combined was 86% against hospitalization and 82% against ED/urgent care encounters.
• For those who visited an ED or urgent care facility, 28.9% of unvaccinated patients tested positive for SARS-CoV-2, while only 7% of those who were vaccinated did.
• The CDC said the protection levels are similar to those seen before the delta variant became prominent.

Moderna has lost ~7.6% in the pre-market after the company announced the first interim dataset from its Phase 1 program for quadrivalent seasonal flu vaccine candidate, mRNA-1010

Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed.

Phase 2 dose-confirmation study was fully enrolled in November (N=500); preparation for Phase 3 study underway.

Seasonal flu program now moving beyond quadrivalent: announcing mRNA-1011 & mRNA-1012 development candidates.